{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T06:26:45Z","timestamp":1794724005652,"version":"4.9.1"},"reference-count":88,"publisher":"BMJ","issue":"3","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Gut"],"accepted":{"date-parts":[[2024,11,3]]},"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:p>Clinically effective pharmacological treatment(s) for metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form metabolic dysfunction-associated steatohepatitis (MASH) represent a largely unmet need in medicine. Since glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been licensed for the treatment of type 2 diabetes mellitus and obesity, they were one of the first drug classes to be examined in individuals with MASLD\/MASH. Successful phase 2 randomised clinical trials with these agents have resulted in progression to phase 3 clinical trials (principally testing the long-term efficacy of subcutaneous semaglutide). Over the last few years, in addition to GLP-1RAs, newer agents with glucose-dependent insulinotropic peptide and\/or glucagon receptor agonist functions have been tested, with increasing evidence from phase 2 randomised clinical trials of histological improvements in MASLD\/MASH, as well as benefits on MASLD-related extrahepatic complications. Based on this background of evidence, single, dual or triple incretin receptor agonists are becoming an attractive and promising treatment option for MASLD or MASH, particularly in individuals with coexisting obesity or type 2 diabetes mellitus. In this narrative review, we examine the rapidly expanding body of clinical evidence supporting a role of incretin-based pharmacotherapies in delaying or reversing MASH progression. We also discuss the biology of incretins and the putative hepatoprotective mechanisms of incretin-based pharmacotherapies for managing MASLD or MASH.<\/jats:p>","DOI":"10.1136\/gutjnl-2024-334023","type":"journal-article","created":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T13:20:57Z","timestamp":1732627257000},"page":"487-497","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":54,"title":["Recent advances in incretin-based therapy for MASLD: from single to dual or triple incretin receptor agonists"],"prefix":"10.1136","volume":"74","clinical-trial-number":[{"clinical-trial-number":"nct04822181","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05364931","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4325-3900","authenticated-orcid":false,"given":"Giovanni","family":"Targher","sequence":"first","affiliation":[{"name":"Metabolic Diseases Research Unit, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar di Valpolicella, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7271-6329","authenticated-orcid":false,"given":"Alessandro","family":"Mantovani","sequence":"additional","affiliation":[{"name":"Endocrinology and Metabolism, University of Verona Faculty of Medicine and Surgery, Verona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6322-7753","authenticated-orcid":false,"given":"Christopher D","family":"Byrne","sequence":"additional","affiliation":[{"name":"Southampton General Hospital, Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4235-2579","authenticated-orcid":false,"given":"Herbert","family":"Tilg","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology & Metabolism, Medizinische Universitat Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,11,26]]},"reference":[{"key":"2025112108352994000_74.3.487.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01701-3"},{"key":"2025112108352994000_74.3.487.2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(22)00317-X"},{"key":"2025112108352994000_74.3.487.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2024.02.007"},{"key":"2025112108352994000_74.3.487.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2020.154170"},{"key":"2025112108352994000_74.3.487.5","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2023-330595"},{"key":"2025112108352994000_74.3.487.6","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-322572"},{"key":"2025112108352994000_74.3.487.7","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-323082"},{"key":"2025112108352994000_74.3.487.8","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2023-330596"},{"key":"2025112108352994000_74.3.487.9","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15930"},{"key":"2025112108352994000_74.3.487.10","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-023-05956-x"},{"key":"2025112108352994000_74.3.487.11","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-024-00979-9"},{"key":"2025112108352994000_74.3.487.12","doi-asserted-by":"publisher","DOI":"10.2337\/dci24-0003"},{"key":"2025112108352994000_74.3.487.13","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00013.2014"},{"key":"2025112108352994000_74.3.487.14","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00034.2006"},{"key":"2025112108352994000_74.3.487.15","doi-asserted-by":"crossref","DOI":"10.1177\/1179551419888871","article-title":"Nonclassical Islet Peptides: Pancreatic and Extrapancreatic Actions","volume":"12","author":"English","year":"2019","journal-title":"Clin Med Insights Endocrinol Diabetes"},{"key":"2025112108352994000_74.3.487.16","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.84.10.3434"},{"key":"2025112108352994000_74.3.487.17","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.49.5.741"},{"key":"2025112108352994000_74.3.487.18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2012.01971.x"},{"key":"2025112108352994000_74.3.487.19","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-009-1643-x"},{"key":"2025112108352994000_74.3.487.20","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3128"},{"key":"2025112108352994000_74.3.487.21","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-009-1611-5"},{"key":"2025112108352994000_74.3.487.22","doi-asserted-by":"publisher","DOI":"10.6065\/apem.2017.22.1.15"},{"key":"2025112108352994000_74.3.487.23","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.153732","article-title":"Differential importance of endothelial and hematopoietic cell GLP-1Rs for cardiometabolic versus hepatic actions of semaglutide","volume":"6","author":"McLean","year":"2021","journal-title":"JCI Insight"},{"key":"2025112108352994000_74.3.487.24","doi-asserted-by":"publisher","DOI":"10.2337\/db14-1577"},{"key":"2025112108352994000_74.3.487.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2023.11.009"},{"key":"2025112108352994000_74.3.487.26","doi-asserted-by":"publisher","DOI":"10.1007\/s13340-017-0317-z"},{"key":"2025112108352994000_74.3.487.27","doi-asserted-by":"crossref","DOI":"10.3390\/nu13020351","article-title":"Incretin Hormones in Obesity and Related Cardiometabolic Disorders: The Clinical Perspective","volume":"13","author":"Micha\u0142owska","year":"2021","journal-title":"Nutrients"},{"key":"2025112108352994000_74.3.487.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2024.05.010"},{"key":"2025112108352994000_74.3.487.29","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(22)00338-7"},{"key":"2025112108352994000_74.3.487.30","doi-asserted-by":"crossref","DOI":"10.3390\/metabo11020073","article-title":"Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials","volume":"11","author":"Mantovani","year":"2021","journal-title":"Metabolites"},{"key":"2025112108352994000_74.3.487.31","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16608"},{"key":"2025112108352994000_74.3.487.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.04.003"},{"key":"2025112108352994000_74.3.487.33","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(23)00068-7"},{"key":"2025112108352994000_74.3.487.34","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000712"},{"key":"2025112108352994000_74.3.487.35","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13751"},{"key":"2025112108352994000_74.3.487.36","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17925"},{"key":"2025112108352994000_74.3.487.37","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2024.04.029"},{"key":"2025112108352994000_74.3.487.38","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2023-330962"},{"key":"2025112108352994000_74.3.487.39","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2024-332687"},{"key":"2025112108352994000_74.3.487.40","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2024.4661"},{"key":"2025112108352994000_74.3.487.41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028395"},{"key":"2025112108352994000_74.3.487.42","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-2151"},{"key":"2025112108352994000_74.3.487.43","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14640"},{"key":"2025112108352994000_74.3.487.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.04.017"},{"key":"2025112108352994000_74.3.487.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.05.013"},{"key":"2025112108352994000_74.3.487.46","doi-asserted-by":"crossref","unstructured":"Harrison SA , Browne SK , Suschak JJ , et al . Effect of pemvidutide, a GLP-1\/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study. J Hepatol 2024. doi:10.1016\/j.jhep.2024.07.006","DOI":"10.1016\/j.jhep.2024.07.006"},{"key":"2025112108352994000_74.3.487.47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401755"},{"key":"2025112108352994000_74.3.487.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.06.003"},{"key":"2025112108352994000_74.3.487.49","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(22)00070-5"},{"key":"2025112108352994000_74.3.487.50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401943"},{"key":"2025112108352994000_74.3.487.51","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03018-2"},{"key":"2025112108352994000_74.3.487.52","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1148209","article-title":"Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent","volume":"14","author":"Mehdi","year":"2023","journal-title":"Front Immunol"},{"key":"2025112108352994000_74.3.487.53","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2024.06.003"},{"key":"2025112108352994000_74.3.487.54","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2023.12.018"},{"key":"2025112108352994000_74.3.487.55","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-005-1787-2"},{"key":"2025112108352994000_74.3.487.56","doi-asserted-by":"publisher","DOI":"10.2337\/db07-1214"},{"key":"2025112108352994000_74.3.487.57","doi-asserted-by":"publisher","DOI":"10.1007\/BF03346367"},{"key":"2025112108352994000_74.3.487.58","doi-asserted-by":"publisher","DOI":"10.1038\/nri1937"},{"key":"2025112108352994000_74.3.487.59","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2009.10.015"},{"key":"2025112108352994000_74.3.487.60","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinsphys.2015.09.001"},{"key":"2025112108352994000_74.3.487.61","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharep.2015.10.008"},{"key":"2025112108352994000_74.3.487.62","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2012.07.086"},{"key":"2025112108352994000_74.3.487.63","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-017-0626-3","article-title":"Liraglutide dictates macrophage phenotype in apolipoprotein E null mice during early atherosclerosis","volume":"16","author":"Bruen","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"2025112108352994000_74.3.487.64","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2011.12.039"},{"key":"2025112108352994000_74.3.487.65","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1163288","article-title":"GLP-1 RAs and SGLT2i: two antidiabetic agents associated with immune and inflammation modulatory properties through the common AMPK pathway","volume":"14","author":"Mazzieri","year":"2023","journal-title":"Front Immunol"},{"key":"2025112108352994000_74.3.487.66","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s42255-018-0001-z","article-title":"GIP regulates inflammation and body weight by restraining myeloid-cell-derived S100A8\/A9","volume":"1","author":"Mantelmacher","year":"2019","journal-title":"Nat Metab"},{"key":"2025112108352994000_74.3.487.67","doi-asserted-by":"crossref","DOI":"10.1186\/s10020-022-00574-6","article-title":"Exenatide regulates Th17\/Treg balance via PI3K\/Akt\/FoxO1 pathway in db\/db mice","volume":"28","author":"Xu","year":"2022","journal-title":"Mol Med"},{"key":"2025112108352994000_74.3.487.68","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2024.05.001"},{"key":"2025112108352994000_74.3.487.69","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00476.2011"},{"key":"2025112108352994000_74.3.487.70","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12120"},{"key":"2025112108352994000_74.3.487.71","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2024.149882"},{"key":"2025112108352994000_74.3.487.72","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2023.101850","article-title":"Evaluation of long acting GLP1R\/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1\/glucagon agonism in NASH patients","volume":"79","author":"Monfeuga","year":"2024","journal-title":"Mol Metab"},{"key":"2025112108352994000_74.3.487.73","doi-asserted-by":"publisher","DOI":"10.1126\/science.adn4128"},{"key":"2025112108352994000_74.3.487.74","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-012-2592-3"},{"key":"2025112108352994000_74.3.487.75","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2018.09.004"},{"key":"2025112108352994000_74.3.487.76","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.119.258343"},{"key":"2025112108352994000_74.3.487.77","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2023.03.016"},{"key":"2025112108352994000_74.3.487.78","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2022.08.003"},{"key":"2025112108352994000_74.3.487.79","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13784"},{"key":"2025112108352994000_74.3.487.80","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2019.10.008"},{"key":"2025112108352994000_74.3.487.81","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.175730"},{"key":"2025112108352994000_74.3.487.82","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00041.2023"},{"key":"2025112108352994000_74.3.487.83","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0165-3806(86)90281-6","article-title":"Development of the optic tract in the cichlid fish Haplochromis burtoni","volume":"391","author":"Presson","year":"1986","journal-title":"Brain Res"},{"key":"2025112108352994000_74.3.487.84","first-page":"S52","article-title":"Role of lifestyle and glucagon-like peptide-1 receptor agonists for weight loss in obesity, type 2 diabetes and steatotic liver diseases","volume":"59 Suppl 1","author":"Giannakogeorgou","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"2025112108352994000_74.3.487.85","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-1508"},{"key":"2025112108352994000_74.3.487.86","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-013-3145-0"},{"key":"2025112108352994000_74.3.487.87","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2023.01.006"},{"key":"2025112108352994000_74.3.487.88","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(22)00003-1"}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gutjnl-2024-334023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T16:35:41Z","timestamp":1763742941000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gutjnl-2024-334023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,26]]},"references-count":88,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,2,6]]},"published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1136\/gutjnl-2024-334023"],"URL":"https:\/\/doi.org\/10.1136\/gutjnl-2024-334023","relation":{},"ISSN":["0017-5749","1468-3288"],"issn-type":[{"value":"0017-5749","type":"print"},{"value":"1468-3288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,26]]}}}